drugset / Trial / NCT07592767
RESvEraTrol in Parkinson's Disease (RESET)
Phase 2
Not yet recruiting
30 enrolled
Georgetown University
Jupiter Neuroscience Inc. · collabMedstar Health Research Institute · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resveratrol | Small molecule | 200 mg | Oral |
| Subject | Resveratrol | Small molecule | 400 mg | Oral |